Search details
1.
Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC).
Br J Cancer
; 130(1): 53-62, 2024 01.
Article
in English
| MEDLINE | ID: mdl-37980367
2.
Fully Automated Versions of Clinically Validated Nephrometry Scores Demonstrate Superior Predictive Utility versus Human Scores.
BJU Int
; 133(6): 690-698, 2024 Jun.
Article
in English
| MEDLINE | ID: mdl-38343198
3.
Parenchymal volume preservation during partial nephrectomy: improved methodology to assess impact and predictive factors.
BJU Int
; 2024 Feb 14.
Article
in English
| MEDLINE | ID: mdl-38355293
4.
Body morphometry may predict parastomal hernia following radical cystectomy with ileal conduit.
BJU Int
; 2024 Jun 17.
Article
in English
| MEDLINE | ID: mdl-38881297
5.
Parenchymal volume analysis to assess longitudinal functional decline following partial nephrectomy.
BJU Int
; 132(4): 435-443, 2023 10.
Article
in English
| MEDLINE | ID: mdl-37409822
6.
Functional recovery after partial nephrectomy: next generation analysis.
BJU Int
; 132(2): 202-209, 2023 08.
Article
in English
| MEDLINE | ID: mdl-37017637
7.
Physiologic tension of the abdominal wall.
Surg Endosc
; 37(12): 9347-9350, 2023 12.
Article
in English
| MEDLINE | ID: mdl-37640951
8.
The association between modifiable perioperative parameters and renal function after nephrectomy.
BJU Int
; 129(3): 380-386, 2022 03.
Article
in English
| MEDLINE | ID: mdl-34196093
9.
Contemporary management of advanced prostate cancer: an evolving landscape.
Clin Adv Hematol Oncol
; 19(2): 108-118, 2021 Feb.
Article
in English
| MEDLINE | ID: mdl-33596192
10.
Impact of 5α-Reductase Inhibitors on Disease Reclassification among Men on Active Surveillance for Localized Prostate Cancer with Favorable Features.
J Urol
; 199(2): 445-452, 2018 02.
Article
in English
| MEDLINE | ID: mdl-28789947
11.
Intermediate-Term Outcomes for Men with Very Low/Low and Intermediate/High Risk Prostate Cancer Managed by Active Surveillance.
J Urol
; 198(3): 591-599, 2017 09.
Article
in English
| MEDLINE | ID: mdl-28347770
12.
Impact of pathologic re-review on grade, clinical stage, and risk stratification for patients with nonmuscle invasive bladder cancer.
Urol Oncol
; 2024 Jun 15.
Article
in English
| MEDLINE | ID: mdl-38880703
13.
Oncologic outcomes of intravesical therapy in the management of nonmuscle invasive bladder cancer with variant histology.
Urol Oncol
; 42(3): 71.e1-71.e7, 2024 03.
Article
in English
| MEDLINE | ID: mdl-38135626
14.
Parenchymal obliteration by renal masses: Functional and oncologic implications.
Urol Oncol
; 42(8): 247.e11-247.e19, 2024 Aug.
Article
in English
| MEDLINE | ID: mdl-38729867
15.
Response to the U.S. Preventative Services Task Force decision on prostate cancer screening.
Curr Urol Rep
; 14(3): 168-73, 2013 Jun.
Article
in English
| MEDLINE | ID: mdl-23568623
16.
Outcomes of Grade Group 2 and 3 Prostate Cancer on Initial Versus Confirmatory Biopsy: Implications for Active Surveillance.
Eur Urol Focus
; 9(4): 662-668, 2023 07.
Article
in English
| MEDLINE | ID: mdl-36566100
17.
AI-generated R.E.N.A.L.+ Score Surpasses Human-generated Score in Predicting Renal Oncologic Outcomes.
Urology
; 180: 160-167, 2023 Oct.
Article
in English
| MEDLINE | ID: mdl-37517681
18.
Using IsoPSA With Prostate Imaging Reporting and Data System Score May Help Refine Biopsy Decision Making in Patients With Elevated PSA.
Urology
; 176: 115-120, 2023 Jun.
Article
in English
| MEDLINE | ID: mdl-36965817
19.
PAM50 and Beyond: When Will Tissue Transcriptomics Guide Clinical Decision-making?
Eur Urol Focus
; 8(4): 916-918, 2022 07.
Article
in English
| MEDLINE | ID: mdl-36031559
20.
Transperineal Prostate Biopsy is Associated With Lower Tissue Core Pathogen Burden Relative to Transrectal Biopsy: Mechanistic Underpinnings for Lower Infection Risk in the Transperineal Approach.
Urology
; 165: 1-8, 2022 07.
Article
in English
| MEDLINE | ID: mdl-35508258